MACK — Merrimack Pharmaceuticals Income Statement
0.000.00%
- $223.75m
- -$20.36m
- 42
- 37
- 78
- 51
Annual income statement for Merrimack Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 22.4 | 2.87 | 2.47 | 1.73 | 2.04 |
Operating Profit | -22.4 | -2.87 | -2.47 | -1.73 | -2.04 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -22.7 | -3.01 | -2.45 | -1.54 | -1.17 |
Provision for Income Taxes | |||||
Net Income After Taxes | -21.3 | -3.03 | -2.46 | -1.54 | -1.18 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -17.3 | -3.03 | -2.46 | -1.54 | -1.18 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -17.3 | -3.03 | -2.46 | -1.54 | -1.18 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.6 | -0.325 | -0.19 | -0.136 | -0.089 |
Special Dividends per Share |